je.st
news
Tag: fda
FDA delays updated \'nutrition facts\' relaunch
2017-07-05 21:13:00| Label and Narrow Web Breaking News
The deadline for which the food industry must comply with the new labeling will be pushed back for an undisclosed time.
Tags: updated
facts
nutrition
delays
FDA Tells Soap Maker to Clean Up Its Website
2017-06-28 13:44:00| Happi Breaking News
Soapwalla has 15 days to fix its product claims.
Tags: website
clean
tells
maker
FDA Issues First Warning Letter in Since February
2017-06-19 20:33:00| Happi Breaking News
Agency cites Salt Lake City, UT skin care company for drug claims on its website.
Tags: since
february
issues
letter
04/25/12 -- Helping The Dairy Industry Meet New FDA Food Handling Requirements
2017-02-08 05:52:19| dairynetwork News Articles
04/25/12 Dairy Network.com Newsletter
Tags: meet
food
industry
requirements
FDA Accepts Two sBLAs for Mercks KEYTRUDA (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings
2017-02-03 12:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Also Receives Breakthrough Therapy Designation for Second-Line Treatment Based on KEYNOTE-045, Which Includes Primary Endpoints of Overall Survival and Progression-Free Survival KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer, a type of bladder cancer. Language: English Contact: For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: advanced
treatment
settings
failure
Sites : [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] next »